• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POSASR filed by Intra-Cellular Therapies Inc.

    4/2/25 4:32:55 PM ET
    $ITCI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ITCI alert in real time by email
    POSASR 1 d936993dposasr.htm POSASR POSASR

    As filed with the Securities and Exchange Commission on April 2, 2025

    Registration No. 333-278726

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Post-Effective Amendment to

    Form S-3

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Intra-Cellular Therapies, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   36-4742850

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

     

    135 Route 202/206, Suite 6

    Bedminster, NJ 07921

      07921
    (Address of principal executive offices)   (Zip code)

     

     

    Randall Nixon

    Secretary

    Intra-Cellular Therapies, Inc.

    135 Route 202/206, Suite 6

    Bedminster, NJ 07921

    (646) 440-9333

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Robert I. Townsend, III

    Ting S. Chen

    Jin-Kyu Baek

    Cravath, Swaine & Moore LLP

    Two Manhattan West

    375 Ninth Avenue

    New York, New York 10001

    (212) 474-1000

     

     

    APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC:

    Not applicable

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☐

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective on filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging Growth Company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for comply with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of Securities Act. ☐

     

     

     


    EXPLANATORY NOTE

    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment No. 1 relates to Automatic Shelf Registration Statement No. 333-278726 on Form S-3 / ASR (the “Registration Statement”), filed by Intra-Cellular Therapies, Inc., a Delaware corporation (the “Company”), with the U.S. Securities and Exchange Commission on April 16, 2024, pertaining to the registration of: (i) an indeterminate number of shares of common stock, par value $0.0001 per share, of the Company (“Common Stock”); (ii) an indeterminate number of shares of preferred stock, par value $0.0001 per share, of the Company (“Preferred Stock”); (iii) an indeterminate principal amount of debt securities; (iv) an indeterminate number of warrants to purchase Common Stock, Preferred Stock or debt securities; (v) an indeterminate number of rights to purchase Common Stock, Preferred Stock or debt securities; and (vi) an indeterminate number of units consisting of the securities described above, in any combination.

    This Post-Effective Amendment is being filed in connection with the closing on April 2, 2025 of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of January 10, 2025 (the “Merger Agreement”), by and among Johnson & Johnson, a New Jersey corporation (“Parent”), Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the Company. On April 2, 2025, pursuant to the Merger Agreement, Merger Sub was merged with and into the Company (the “Merger”), with the Company surviving the Merger and continuing as a wholly owned subsidiary of Parent.

    As a result of the Merger, the Company has terminated all offerings of the Company’s securities pursuant to its existing registration statements under the Securities Act of 1933, as amended (the “Securities Act”), including the Registration Statement. In accordance with undertakings made by the Company in the Registration Statement to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance that remain unsold at the termination of the offering, the Company hereby removes from registration all such securities of the Company registered pursuant to the Registration Statement that remain unsold as of the date hereof. The Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities, and the Registrant hereby terminates the effectiveness of the Registration Statement.


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bedminster, State of New Jersey, on April 2, 2025. No other person is required to sign this Post-Effective Amendment to the Registration Statement in reliance upon Rule 478 under the Securities Act.

     

    INTRA-CELLULAR THERAPIES, INC.
    By:   /s/ Randall Nixon
    Name:   Randall Nixon
    Title:   Secretary
    Get the next $ITCI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ITCI

    DatePrice TargetRatingAnalyst
    2/24/2025$140.00 → $132.00Outperform → Neutral
    Mizuho
    1/31/2025$119.00 → $132.00Buy → Hold
    Canaccord Genuity
    9/6/2024$68.00 → $92.00Neutral → Overweight
    Piper Sandler
    1/3/2024$83.00Outperform
    Robert W. Baird
    12/11/2023$75.00Outperform
    TD Cowen
    4/20/2023$80.00Overweight
    Morgan Stanley
    8/22/2022$64.00 → $49.00Buy → Neutral
    Goldman
    7/7/2022$74.00Buy
    Mizuho
    More analyst ratings

    $ITCI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providersNet revenues of $28.5 million reported for Q1Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwindsStrategic cost reductions and executive leadership changes implemented to support sustainable revenue growth and achieve profit from operations, excluding stock-based compensation, in 2026Management to host conference call today, May 1, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commerciali

      5/1/25 7:00:41 AM ET
      $ITCI
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results

      Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million, representing a 51% increase over the same period in 2023 Full year 2024 CAPLYTA net product sales were $680.5 million, representing year-over-year growth of 47% The U.S. Food and Drug Administration (FDA) accepted for review the lumateperone supplemental New Drug Application (sNDA) submission for adjunctive treatment of major depressive disorder (MDD) BEDMINSTER, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial result

      2/21/25 8:00:48 AM ET
      $ITCI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

      Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has potential to become a standard of care for most common depressive disorders CAPLYTA® adds to Johnson & Johnson's robust lineup of therapies with $5 billion+ potential in peak year salesi and further solidifies sales growth above analyst expectations now through the remainder of the decade Promising clinical-stage pipeline with best-in-disease potent

      1/13/25 6:32:27 AM ET
      $ITCI
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITCI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Intra-Cellular Therapies downgraded by Mizuho with a new price target

      Mizuho downgraded Intra-Cellular Therapies from Outperform to Neutral and set a new price target of $132.00 from $140.00 previously

      2/24/25 7:10:56 AM ET
      $ITCI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intra-Cellular Therapies downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Intra-Cellular Therapies from Buy to Hold and set a new price target of $132.00 from $119.00 previously

      1/31/25 7:02:57 AM ET
      $ITCI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intra-Cellular Therapies upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Intra-Cellular Therapies from Neutral to Overweight and set a new price target of $92.00 from $68.00 previously

      9/6/24 7:44:31 AM ET
      $ITCI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITCI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Intra-Cellular Therapies Inc.

      SC 13G/A - Intra-Cellular Therapies, Inc. (0001567514) (Subject)

      11/12/24 10:32:13 AM ET
      $ITCI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Intra-Cellular Therapies Inc.

      SC 13G - Intra-Cellular Therapies, Inc. (0001567514) (Subject)

      10/10/24 12:36:28 PM ET
      $ITCI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Intra-Cellular Therapies Inc. (Amendment)

      SC 13G/A - Intra-Cellular Therapies, Inc. (0001567514) (Subject)

      2/13/24 5:08:02 PM ET
      $ITCI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITCI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Salas Eduardo Rene returned $206,844 worth of shares to the company (1,567 units at $132.00), closing all direct ownership in the company (SEC Form 4)

      4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)

      4/2/25 8:34:41 PM ET
      $ITCI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Riggs Rory B returned $17,359,584 worth of shares to the company (131,512 units at $132.00), closing all direct ownership in the company (SEC Form 4)

      4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)

      4/2/25 5:47:21 PM ET
      $ITCI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President Halstead Michael returned $2,812,524 worth of shares to the company (21,307 units at $132.00), closing all direct ownership in the company (SEC Form 4)

      4 - Intra-Cellular Therapies, Inc. (0001567514) (Issuer)

      4/2/25 5:46:14 PM ET
      $ITCI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITCI
    Leadership Updates

    Live Leadership Updates

    See more
    • Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer

      NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sanjeev Narula will join the Company on August 12, 2024 and will serve as Executive Vice President, Chief Financial Officer. Mr. Narula will report to Dr. Sharon Mates, ITCI's Chairman and Chief Executive Officer. Lawrence Hineline, who currently serves as Chief Financial Officer, will retire on the same date but will continue to serve as a consultant to the Company for a period of time to ensure a smooth transition. "I am excited to welcome Mr.

      8/7/24 7:40:54 AM ET
      $ITCI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intra-Cellular Therapies Announces Appointment of E. Rene Salas to Board of Directors

      NEW YORK, April 21, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the appointment of E. Rene Salas to the Intra-Cellular Therapies Board of Directors. Mr. Salas will serve as a member of the audit committee. "We are pleased to welcome Rene Salas to the Intra-Cellular Therapies Board," said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. "Rene's extensive financial and life sciences advisory experience will be very valuable as we continue to grow our business and pursue our mission to develop innova

      4/21/22 8:00:00 AM ET
      $ITCI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cibus Appoints Co-Founder Rory Riggs, as Chief Executive Officer

      Cibus, a leading agricultural biotechnology company, announced today the appointment of Rory Riggs, co-founder, and Chairman of Cibus, to serve as Chief Executive Officer. He will succeed Peter Beetham, PhD, also a Cibus co-founder, who has been appointed President and Chief Operating Officer of the 20-year-old company. "Since our founding, Rory has been an important strategic partner in the success of Cibus and we are pleased that he is deepening his involvement in the company's growth as CEO," said Dr. Beetham. "With the recent progress toward a European approval of Cibus' proprietary precision gene-editing technology, as well as other recent Cibus commercial announcements, this manageme

      10/7/21 9:00:00 AM ET
      $FGEN
      $ITCI
      $RPRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITCI
    SEC Filings

    See more
    • SEC Form 15-12G filed by Intra-Cellular Therapies Inc.

      15-12G - Intra-Cellular Therapies, Inc. (0001567514) (Filer)

      4/14/25 8:55:29 AM ET
      $ITCI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Intra-Cellular Therapies Inc.

      EFFECT - Intra-Cellular Therapies, Inc. (0001567514) (Filer)

      4/10/25 12:15:05 AM ET
      $ITCI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POSASR filed by Intra-Cellular Therapies Inc.

      POSASR - Intra-Cellular Therapies, Inc. (0001567514) (Filer)

      4/2/25 4:32:55 PM ET
      $ITCI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ITCI
    Financials

    Live finance-specific insights

    See more
    • Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      VOQUEZNA launch momentum continues with over 390,000 prescriptions filled to date, written by more than 23,600 healthcare providersNet revenues of $28.5 million reported for Q1Filled VOQUEZNA prescriptions increased ~8% in Q1 over the prior quarter despite seasonal headwindsStrategic cost reductions and executive leadership changes implemented to support sustainable revenue growth and achieve profit from operations, excluding stock-based compensation, in 2026Management to host conference call today, May 1, 2025, at 8:00 a.m. ET FLORHAM PARK, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commerciali

      5/1/25 7:00:41 AM ET
      $ITCI
      $PHAT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results

      Fourth quarter 2024 CAPLYTA net product sales grew to $199.2 million, representing a 51% increase over the same period in 2023 Full year 2024 CAPLYTA net product sales were $680.5 million, representing year-over-year growth of 47% The U.S. Food and Drug Administration (FDA) accepted for review the lumateperone supplemental New Drug Application (sNDA) submission for adjunctive treatment of major depressive disorder (MDD) BEDMINSTER, N.J., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial result

      2/21/25 8:00:48 AM ET
      $ITCI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

      Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has potential to become a standard of care for most common depressive disorders CAPLYTA® adds to Johnson & Johnson's robust lineup of therapies with $5 billion+ potential in peak year salesi and further solidifies sales growth above analyst expectations now through the remainder of the decade Promising clinical-stage pipeline with best-in-disease potent

      1/13/25 6:32:27 AM ET
      $ITCI
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care